7 of the Best Pharma Stocks to Buy Now

investorplace2021-05-12

During the past year, there was a justifiable obsession with the race to a vaccine for the novel coronavirus. And the companies in that race were making headlines constantly, with prices for longshots...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

DiamondsHand
2021-05-13
DiamondsHand
MNMD ?
Zack克明冲
2021-05-12
Zack克明冲
How about$Cocrystal Pharma, Inc.(COCP)$n$Athenex Inc.(ATNX)$highly potential options to consider on!Something good wil happen to ATNX!
jiaxinn
2021-05-12
jiaxinn
Great stock ideas
jw321
2021-05-12
jw321
hello
Bodoh
2021-05-12
Bodoh
Everything is a buy?!
ADT
2021-05-12
ADT
Commented

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1188302067?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-05-12 08:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188302067","market":"us","top_or_hot":-1,"title":"7 of the Best Pharma Stocks to Buy Now","media":"investorplace","content":"<div>\n<p>During the past year, there was a justifiable obsession with the race to a vaccine for the novel coronavirus. And the companies in that race were making headlines constantly, with prices for longshots...</p>\n\n<a href=\"https://investorplace.com/2021/05/7-of-the-best-pharma-stocks-to-buy-now/\">Source Link</a>\n\n</div>\n","source":"lsy1606302653667","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>7 of the Best Pharma Stocks to Buy Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n7 of the Best Pharma Stocks to Buy Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-12 08:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/7-of-the-best-pharma-stocks-to-buy-now/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>During the past year, there was a justifiable obsession with the race to a vaccine for the novel coronavirus. And the companies in that race were making headlines constantly, with prices for longshots...</p>\n\n<a href=\"https://investorplace.com/2021/05/7-of-the-best-pharma-stocks-to-buy-now/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SWTX","symbol_name":"SpringWorks Therapeutics, Inc.","start_time":0,"source_url":"https://investorplace.com/2021/05/7-of-the-best-pharma-stocks-to-buy-now/","article_id":"1188302067","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188302067","pubTimestamp":1620780137,"sourceInfo":{"source_id":"lsy1606302653667","name":"InvestorPlace"},"weMediaInfo":null,"summary":"During the past year, there was a justifiable obsession with the race to a vaccine for the novel cor","collect":0,"end_time":0,"defaultTopTitle":"investorplace.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SWTX":"SpringWorks Therapeutics, Inc.","HZNP":"Horizon Pharma","ALLK":"Allakos Inc.","SAGE":"Sage Therapeutics","MNMD":"Mind Medicine (MindMed) Inc.","IMAB":"天境生物","IBRX":"ImmunityBio, Inc."},"translate_title":"目前最好买的7只医药股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALLK":0.9,"HZNP":0.9,"IBRX":0.9,"IMAB":0.9,"MNMD":0.9,"SAGE":0.9,"SWTX":0.9},"content_text":"During the past year, there was a justifiable obsession with the race to a vaccine for the novel coronavirus. And the companies in that race were making headlines constantly, with prices for longshots soaring and even the big players were riding the tide.\nBut there are a couple realities to vaccine production. First, vaccines aren’t big money makers. And as you can see by the recent proposal from President Biden, the intellectual property may well be distributed for free to rid the globe of the pandemic.\nThis was always the story for people who understood how pharma stocks work. You get broad distribution of a vaccine, but the margins are very slim. If you want to make money in the pharma sector, you need to find a therapy for something everyone has or very few people have. That’s where the margins are and the long-term growth of a company.\nNow that vaccinations are almost off the front page, here are seven of the best pharma stocks to buy now.\n\nHorizon Therapeutics(NASDAQ:HZNP)\nImmunityBio(NASDAQ:IBRX)\nI-Mab(NASDAQ:IMAB)\nMind Medicine(NASDAQ:MNMD)\nSage Therapeutics(NASDAQ:SAGE)\nSpringWorks Therapeutics(NASDAQ:SWTX)\nAllakos(NASDAQ:ALLK)\n\nPharma Stocks to Buy: Horizon Therapeutics (HZNP)\nWhile 97% of its sales are in the U.S., HZNP is one of those pharmaceuticals that moved its operations to Ireland for favorable tax status. With a $20 billion market cap, it’s one of the biggest pharma stocks on our list.\nWhat’s more, it has a handful of drugs already in the market, earning money. HZNP focuses on rheumatic diseases as well as rare and orphan diseases. The rheumatic diseases like gout, mean long-term therapies as do the rare diseases. And the rare diseases usually only have one or two drugs to treat them, although their patient pool is small.\nBut the big thing with HZNP is, it already has drugs in the marketplace and that’s a big deal because getting drugs approved is costly and time-consuming. That’s a distinct competitive advantage. It also has a solid pipeline.\nHZNP stock is up 18% year to date. It has an ‘A’ rating in my Portfolio Grader.\nImmunityBio (IBRX)\nThe one holy grail of vaccines — essentially therapeutic drugs that activate the human immune system to fight diseases — is that they’re potentially useful against any number of issues beyond viruses. Take, for example, cancer.\nIBRX is one of the pharma stocks that is taking immuno-therapies to the next level. What’s more, it was actually accepted in Operation Light Speed for its Covid-19 vaccine. And it’s still working with the South African government on a distribution plan for the drug that currently in phase 1 trials.\nIt has a $6 billion market cap after a healthy run in 2020, and is up 21% year to date. The added investment capital will help boost research and development.\nIt has an ‘A’ rating in my Portfolio Grader.\nPharma Stocks to Buy: I-Mab (IMAB)\nOne of the big long-term themes in the markets is the rise of China. Within the next decade or less, it’s going to overtake the U.S. as the largest economy in the world. And given its history with the West going back to the Opium Wars and beyond, it is very motivated to create its own economy and not rely on the West to provide its products, science, engineering and technology.\nFor investors, that means it’s wise to find good China-based firms that are making headway in China and the global markets. IMAB is one of them and is becoming one of the world’s pharma stocks to pay attention to.\nIMAB is a development stage biotech that focuses on immuno-oncology and immuno-inflammation. It has drugs in phase 2/3 trials China a couple in phase 1 trials in the U.S.\nIt has a $4 billion market cap and offers exposure to one of the fastest growing pharma markets in the world. IMAB is up 25.8% year to date.\nMind Medicine (MNMD)\nIf you’re looking to take a step beyond in your portfolio, MNMD, colloquially known as MindMed may be just the ticket.\nIt is working in the U.S. and Europe in a sector most pharma stocks haven’t even thought about exploring — psychedelics as drug therapies for addiction, depression, PTSD, adult ADHD and anxiety. It has ongoing research in Basel, Switzerland, the birthplace of LSD, as well as the University of Maastricht in the Netherlands and New York University.\nFor many decades research into these drugs was strictly forbidden in the U.S. by law and U.S. institutions couldn’t get government funding for independent research. But that is all changing and decades of research from abroad is now being confirmed in recent studies.\nMNDM only has a market cap of $3 million and is trading near the bottom of its 52-week range. It’s speculative but may be worth some risk capital if you believe in this therapeutic concept.\nIt has an ‘A’ rating in my Portfolio Grader.\nPharma Stocks to Buy: Sage Therapeutics (SAGE)\nIf psychedelics aren’t your thing, but you’re interested in drugs to help with mental health issues, then SAGE may be of interest to you.\nWhile there are plenty of pharma stocks that offer typical treatments for depression and other chronic mental health issues, SAGE is exploring a new and broader effort to address neuroscience drug development that also includes treatments for Parkinson’s, Alzheimer’s and Huntington’s diseases.\nZulresso is its first drug out of trials and it’s focused on post-partum depression. But SAGE has a number of trials underway and is partnered with a major drug company for two of its drugs, which are progressing nicely.\nSAGE stock is off 11% year to date, trading at a current P/E of 6, with a $4 billion market cap. Tempting.\nIt has an ‘A’ rating in my Portfolio Grader.\nSpringWorks Therapeutics (SWTX)\nLaunched in 2017, SWTX is a clinical-stage biopharmaceutical company that focuses on rare diseases and cancers. It has partnerships with a number of major pharma companies on its work in multiple myeloma and tumor therapies. It’s currently in phase 3 clinical trials for its drug to treat desmoid tumors (debilitating and disfiguring soft tumors).\nSWTX has eight drugs and combination therapies in trials and one in preclinical trials. And most of trials are sponsored by a major pharma company, which is a good sign the therapy has potential.\nAlso, with a $3 billion market cap, it’s an attractive target for an acquisition by one of the larger pharma companies it’s working with.\nThe stock is up 2% year to date and like most clinical-stage pharma stocks, it’s a pure play on its pipeline now, rather than revenue. That’s also where big partners help manage burn and drug rollout.\nIt has an ‘A’ rating in my Portfolio Grader.\nPharma Stocks to Buy: Allakos (ALLK)\nThis clinical-stage biotech develops antibodies to help treat allergic, inflammatory and proliferative diseases. The latter basically means any disease where the cells grow in number rapidly, like tumor growth. ALLK’s most advanced trials are focused on eosinophilic gastrointestinal diseases (EGIDs).\nThere are a number of different conditions that would benefit from ALLK’s work in this area and its approach is fairly unique for pharma stocks exploring these treatment areas.\nALLK has had a wild 52-week ride, from a low around $60 to a high around $158. ALLK stock is off 32% year to date and sits around $90 at this point. It has a $5 billion market cap, so it’s a potential buyout target as well … if its drugs work out.\nIt has a ‘B’ rating in my Portfolio Grader.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":191456857,"gmtCreate":1620902179579,"gmtModify":1704350148877,"author":{"id":"3578113539215777","authorId":"3578113539215777","name":"DiamondsHand","avatar":"https://static.tigerbbs.com/bbb5d1bf66dee2f5259e3d141daff82e","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3578113539215777","idStr":"3578113539215777"},"htmlText":"MNMD ?&nbsp;","listText":"MNMD ?&nbsp;","text":"MNMD ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/191456857","repostId":1188302067,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":193222565,"gmtCreate":1620792969857,"gmtModify":1704348492800,"author":{"id":"3574222119045289","authorId":"3574222119045289","name":"Zack克明冲","avatar":"https://static.tigerbbs.com/87d4276781b63267606929e671232344","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3574222119045289","idStr":"3574222119045289"},"htmlText":"How about<a href=\"https://laohu8.com/S/COCP\">$Cocrystal Pharma, Inc.(COCP)$</a>n<a href=\"https://laohu8.com/S/ATNX\">$Athenex Inc.(ATNX)$</a>highly potential options to consider on!Something good wil happen to ATNX!","listText":"How about<a href=\"https://laohu8.com/S/COCP\">$Cocrystal Pharma, Inc.(COCP)$</a>n<a href=\"https://laohu8.com/S/ATNX\">$Athenex Inc.(ATNX)$</a>highly potential options to consider on!Something good wil happen to ATNX!","text":"How about$Cocrystal Pharma, Inc.(COCP)$n$Athenex Inc.(ATNX)$highly potential options to consider on!Something good wil happen to ATNX!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/193222565","repostId":1188302067,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":193683424,"gmtCreate":1620784046868,"gmtModify":1704348322295,"author":{"id":"3581064561151865","authorId":"3581064561151865","name":"jiaxinn","avatar":"https://static.tigerbbs.com/2ecddbc051d92ef98a3d39070110ff97","vip":1,"crmLevel":4,"crmLevelSwitch":0,"authorIdStr":"3581064561151865","idStr":"3581064561151865"},"htmlText":"Great stock ideas","listText":"Great stock ideas","text":"Great stock ideas","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/193683424","repostId":1188302067,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":193614499,"gmtCreate":1620783807711,"gmtModify":1704348318029,"author":{"id":"3574053691106982","authorId":"3574053691106982","name":"jw321","avatar":"https://static.tigerbbs.com/1263b51c7856e75fbd5cf4072078ca6e","vip":1,"crmLevel":3,"crmLevelSwitch":0,"authorIdStr":"3574053691106982","idStr":"3574053691106982"},"htmlText":"hello","listText":"hello","text":"hello","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/193614499","repostId":1188302067,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":193607764,"gmtCreate":1620782541058,"gmtModify":1704348280542,"author":{"id":"3559859558754319","authorId":"3559859558754319","name":"Bodoh","avatar":"https://static.tigerbbs.com/349218ea2852130ca86ce660b4aa2d59","vip":1,"crmLevel":3,"crmLevelSwitch":0,"authorIdStr":"3559859558754319","idStr":"3559859558754319"},"htmlText":"Everything is a buy?!","listText":"Everything is a buy?!","text":"Everything is a buy?!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/193607764","repostId":1188302067,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":193848532,"gmtCreate":1620781454226,"gmtModify":1704348248601,"author":{"id":"3569983505645625","authorId":"3569983505645625","name":"ADT","avatar":"https://static.tigerbbs.com/e93afb2ccf01f9bdbba38c101f052296","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3569983505645625","idStr":"3569983505645625"},"htmlText":"Commented&nbsp;","listText":"Commented&nbsp;","text":"Commented","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/193848532","repostId":1188302067,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":37,"commentSize":9,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1188302067"}